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Abstract
Purpose—The operational elements essential for establishing an inpatient pharmacogenetic 
service are reviewed, and the role of the pharmacist in the provision of genotype-guided drug 
therapy in pharmacogenetics programs at three institutions is highlighted.
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Summary—Pharmacists are well positioned to assume important roles in facilitating the clinical 
use of genetic information to optimize drug therapy given their expertise in clinical pharmacology 
and therapeutics. Pharmacists have assumed important roles in implementing inpatient 
pharmacogenetics programs. This includes programs designed to incorporate genetic test results to 
optimize antiplatelet drug selection after percutaneous coronary intervention and personalize 
warfarin dosing. Pharmacist involvement occurs on many levels, including championing and 
leading pharmacogenetics implementation efforts, establishing clinical processes to support 
genotype-guided therapy, assisting the clinical staff with interpreting genetic test results and 
applying them to prescribing decisions, and educating other healthcare providers and patients on 
genomic medicine. The three inpatient pharmacogenetics programs described use reactive versus 
preemptive genotyping, the most feasible approach under the current third-party payment 
structure. All three sites also follow Clinical Pharmacogenetics Implementation Consortium 
guidelines for drug therapy recommendations based on genetic test results.
Conclusion—With the clinical emergence of pharmacogenetics into the inpatient setting, it is 
important that pharmacists caring for hospitalized patients are well prepared to serve as experts in 
interpreting and applying genetic test results to guide drug therapy decisions. Since genetic test 
results may not be available until after patient discharge, pharmacists practicing in the ambulatory 
care setting should also be prepared to assist with genotype-guided drug therapy as part of 
transitions in care.
Keywords
clopidogrel; genotype; inpatient; pharmacists; pharmacogenetics; warfarin
Drug complications are the most common type of adverse event in hospitalized patients and 
are associated with significant morbidity, mortality, and healthcare costs.1–3 Anticoagulant 
and cardiovascular medications are among the top causes of drug-related adverse events 
during hospitalization.1 Pharmacogenetics has the potential to improve the safety and 
effectiveness of medications prescribed during hospitalization, potentially improving patient 
outcomes and reducing healthcare costs. Pharmacists have long been at the forefront of 
scientific discovery in the field of pharmacogenetics, generating evidence to support its 
clinical implementation. Now that pharmacogenetics is entering clinical practice for some 
drugs, pharmacists are well positioned to serve integral roles in translating genetic 
discoveries to drug therapy decisions, given their extensive education and training in 
pharmacology and therapeutics. According to ASHP, every pharmacist should be 
knowledgeable about genetic contributions to drug response and serve as a key resource for 
interpreting genetic test results and applying genetic information to drug therapy decisions.4 
Specially trained pharmacists may serve in leadership roles in multidisciplinary efforts to 
establish genotype-guided drug therapy as part of clinical care, and postgraduate residencies 
and fellowships have emerged to provide such specialty training at institutions currently 
implementing pharmacogenetics.
Pharmacists also have leading roles in the development of guidelines by the Clinical 
Pharmacogenetics Implementation Consortium (CPIC), which are designed to assist 
clinicians with interpreting genetic test results and applying these results to therapeutic 
decisions.5 As of late 2015, CPIC guidelines were available for 17 drugs or drug classes, 
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including a number of drugs commonly initiated in the inpatient setting (e.g., thiopurines, 
clopidogrel, warfarin, codeine, carbamazepine). This review focuses on pharmacogenetics 
implementation for cardiovascular drugs in the inpatient setting, specifically summarizing 
the data supporting implementation of genotype-guided antiplatelet and warfarin therapies 
and describing the operational elements of pharmacogenetics programs for these drugs, 
including unique aspects with implementation in the inpatient setting. Specific examples of 
pharmacogenetics programs to optimize antiplatelet drug selection and improve warfarin 
dosing in the inpatient setting are also described.
Data supporting pharmacogenetics implementation and implementation 
guidelines
Clopidogrel
Clopidogrel is a prodrug that requires hepatic biotransformation to its pharmacologically 
active thiol metabolite, which inhibits the platelet P2Y12 receptor to prevent platelet 
activation and subsequent aggregation. Cytochrome P-450 (CYP) isozyme 2C19 is involved 
in both steps of the biotransformation pathway. Genetic variation leading to deficiency of 
CYP2C19 function results in reduced production of the active thiol metabolite and decreased 
inhibition of platelet aggregation with clopidogrel.6
The CYP2C19*1/*1 genotype is associated with “normal” enzyme activity and confers the 
extensive metabolizer (EM) phenotype. The most commonly described CYP2C19 loss-of-
function variants are the CYP2C19*2 and CYP2C19*3 alleles, which result from a splicing 
defect and stop codon, respectively. Additional loss-of-function alleles include the 
CYP2C19*4, CYP2C19*5, and CYP2C19*6 alleles. Individuals with a single loss-of-
function allele (e.g., CYP2C19*1/*2 genotype) have the intermediate metabolizer (IM) 
phenotype, while those with two loss-of-function alleles (e.g., CYP2C19*2/*2 or 
CYP2C19*2/*3 genotype) have the poor metabolizer (PM) phenotype. Approximately 30% 
of whites, 35% of blacks, and 65% of Asians have the PM or IM phenotype.7 Two additional 
phenotypes—rapid metabolizer (RM) and ultrarapid metabolizer (UM)—occur in the 
presence of one or two gain-of-function CYP2C19*17 alleles, respectively. However, the 
clinical implications of the CYP2C19*17 allele remain unclear, and guidelines provide 
similar recommendations for antiplatelet therapy selection in RMs, UMs, and EMs.8
Numerous studies have documented an increased risk of adverse cardiovascular events after 
acute coronary syndrome and percutaneous coronary intervention (PCI) in clopidogrel-
treated patients with the PM or IM phenotype, compared with similarly treated patients with 
the EM, RM, or UM phenotype.9,10 The Food and Drug Administration (FDA) approved a 
boxed warning on the clopidogrel labeling in 2010 regarding reduced effectiveness in PMs 
and recommending alternative therapy in such patients.11 Neither prasugrel nor ticagrelor is 
affected by the CYP2C19 genotype.12,13 Thus, CPIC guidelines recommend alternative 
therapy with prasugrel or ticagrelor (in the absence of contraindications) in patients with a 
loss-of-function allele after acute coronary syndrome and PCI.8
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Warfarin
There is substantial variability in the warfarin dose needed for therapeutic anticoagulation, 
with dose requirements varying over 20-fold among patients.14 Studies have consistently 
shown that the CYP2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotypes 
contribute to the variability in warfarin dose requirements.15 The CYP2C9 gene encodes for 
the enzyme that metabolizes the more potent S-warfarin enantiomer, while VKORC1 
encodes for the target protein of warfarin. The most common CYP2C9 variants in whites are 
the CYP2C9*2 and CYP2C9*3 alleles, each resulting from a single nucleotide 
polymorphism in the gene coding region.15 The CYP2C9*2 and CYP2C9*3 alleles reduce 
enzyme activity and confer lower warfarin dose requirements.16 Additional variants, namely 
the CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 alleles, occur almost exclusively 
in blacks and also reduce enzyme activity and dose requirements.17–19 A single variant, 
-1639G>A, occurs in the VKORC1 gene regulatory region and influences gene expression, 
with reduced expression and lower warfarin dose requirements with the -1639A allele.20 The 
CYP4F2 gene, which is involved in the metabolism of vitamin K, also affects warfarin dose 
requirements, with higher doses required in carriers of a 433Met allele.21,22 In addition to 
influencing dose requirements, the CYP2C9 and VKORC1 variants were recently associated 
with an increased risk for major bleeding events with warfarin.23
Two prospective clinical trials examining the efficacy of genotype-guided warfarin dosing 
yielded disparate results. A European trial showed improved anticoagulation with genotype-
guided dosing versus a traditional dosing approach.24 In contrast, a U.S. trial in a diverse 
patient population showed no benefit in the time spent in the therapeutic International 
Normalized Ratio (INR) range using a pharmacogenetics algorithm including both genotype 
and clinical factors versus dosing with an algorithm containing clinical factors alone.25 
There were a number of differences between the two studies that have been postulated as 
contributors to the disparate results, including differences in study populations, comparator 
groups, loading-dose regimens, and pharmacogenetic algorithms, which are summarized 
elsewhere.26 An important criticism of the U.S. trial is that approximately one third of the 
population was black, yet many of the common genetic alleles contributing to warfarin dose 
requirements in blacks were not tested. Specifically, both trials limited genotyping to the 
VKORC1 -1639G>A and CYP2C9*2 and CYP2C9*3 alleles, which are the most common 
alleles contributing to warfarin dose requirements in whites. Failure to test for the 
CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 alleles and other alleles contributing 
to warfarin dose requirements in blacks may have influenced the accuracy of genotype-
guided warfarin dosing in this population.17,27,28 The pharmacogenetic algorithm used in the 
U.S. trial was significantly better than the clinical algorithm at predicting warfarin dose 
requirements in nonblacks but performed worse than the clinical algorithm in blacks.
Despite the inconsistencies in study results, genotype-guided dosing has entered clinical 
practice in some institutions, with preliminary evidence of improved anticoagulation-related 
outcomes with this approach, as described below.29 CPIC guidelines recommend the use of 
genetic information to guide warfarin dosing when such information exists and the use of 
pharmacogenetic algorithms that incorporate clinical and genetic factors to assist with 
dosing.15
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Operational elements
Pharmacogenetics implementation requires a multidisciplinary team approach. While the 
size of the team may vary by institution and complexity of the implementation, it usually 
consists of at least one individual with expertise in each of the following areas: 
pharmacogenetics, clinical care in the area of implementation, laboratory medicine, and 
health informatics. Pharmacists are important members of the multidisciplinary team, in 
some instances serving as champions of implementation efforts.30,31 In other instances, 
pharmacists play critical roles in establishing the processes to support genetic testing and 
facilitating incorporation of genetic test results into clinical decisions.32 Many pharmacists 
involved in the clinical implementation of pharmacogenetics have formal education and 
postdoctoral residency or fellowship training in pharmacogenetics or a related specialty area 
(e.g., oncology).33 Specialized certificate training and continuing-education programs are 
also beginning to emerge to help prepare pharmacists without formalized education and 
training to provide genotype-guided therapy.34–36 In spite of an increased availability of 
such programs, postgraduate training and education opportunities for pharmacogenetics 
remain limited, and there is a significant need in this area.33 Common steps for 
implementing pharmacogenetics in the inpatient setting are summarized in Figure 1, in 
addition to important questions to consider before implementation. The following sections 
summarize key considerations in the implementation process, including those unique to the 
inpatient setting.
Selection and institutional approval of pharmacogenetic tests for clinical use
The initial step in the implementation process is a review of the evidence to determine 
whether the data are sufficient to support clinical application of genetic test results. 
PharmGKB, a pharmacogenomics knowledge base, serves as a key resource in this regard. 
PharmGKB is a centralized resource for pharmacogenetic data and is publicly accessible 
through its website, www.pharmgkb.org.37 PharmGKB has established a framework for 
evaluating the quality of pharmacogenetic evidence, with the strongest (high) evidence 
ranked as level 1 and the weakest (preliminary) as level 4. Levels 1 and 2 are further 
classified as A or B, with level 1A indicating that a gene–drug pair has a CPIC-endorsed or 
medical society– endorsed guideline or is supported by an existing clinical implementation 
within a major health system. Accordingly, most pharmacogenetics implementation efforts 
target gene–drug pairs with level 1A evidence. Each peer-reviewed, consensus-based CPIC 
guideline is published in Clinical Pharmacology and Therapeutics and indexed by the 
National Guidelines Clearinghouse, with select guidelines endorsed by ASHP.38 In addition, 
the PharmGKB website houses additional clinical implementation resources for each 
guideline, including tools for in terpreting genotype results, genotype translation and 
frequency tables, links to additional professional guidelines, and sample clinical decision 
support tools.37 The goal of CPIC is not to recommend whether genetic testing should be 
done, leaving this to the discretion of the clinician. Rather, CPIC provides guidance on how 
to use existing genetic test results to optimize pharmacotherapy.38
Although not always necessary, another important step in the implementation process may 
be to obtain appropriate administrative and institutional approval to establish testing as part 
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of clinical care. On the inpatient side, the pharmacy and therapeutics (P&T) committee and 
the medical executive committee often serve as the regulatory approval bodies for 
pharmacogenetics implementation, though additional approvals may be necessary from other 
regulatory bodies (e.g., anticoagulation task force, clinical decision support committee). 
Institutional endorsement of the program may also help to support the program’s success. 
For example, in instances where genetic testing is not reimbursed by third-party payers, the 
hospital must be willing to assume this cost.
Establishing genotyping procedures
Genetic testing is offered through a number of commercial laboratories. For institutions 
choosing to establish genetic testing inhouse, selection of the genotyping methodology is 
another critical component in the implementation process. Examples of FDA-cleared 
platforms for pharmacogenetic testing are provided in the appendix.39 Laboratories may also 
choose to develop their own tests. Genetic testing must be established in accordance with 
Clinical Laboratory Improvement Amendments (CLIA) licensure and be accredited by the 
College of American Pathologists (CAP) in order for test results to be integrated into the 
electronic health record (EHR) and used for clinical decision-making.40 Genetic testing is 
considered high-complexity testing by CLIA, which prevents the use of bedside testing 
outside of a CLIA- or CAP-accredited process and creates a challenge when genetic test 
results are needed quickly to influence acute drug therapy decisions.40
Key considerations in choosing genotype methodology are the complexity of the test 
procedure and the turnaround for test results. In the inpatient setting, efficient attainment of 
test results is warranted so that results are available quickly to influence drug decisions. 
Rapid turnaround of test results is not always possible; thus, there should be a process in 
place for communicating results to providers after the patient is discharged. For example, at 
University of Florida (UF) Health, where CYP2C19 testing is clinically available to assist 
with the selection of anti-platelet therapy after PCI, the mean test turnaround time is two to 
four business days. Patients may be discharged by the time genotype results are returned, 
especially if the PCI is done electively. In this case, the clinical pharmacist notifies the 
provider caring for the patient after discharge and recommends an alternative antiplatelet 
agent if a loss-of-function variant is detected.31
Another important consideration is which genetic variants to test for, especially considering 
ethnic differences in genotype frequencies. For example, approximately 15–20% of African 
Americans have a CYP2C9*5, CYP2C9*6, CYP2C9*8, or CYP2C9*11 allele, whereas only 
about 6% have a CYP2C9*2 or CYP2C9*3 allele. If only the CYP2C9*2 and CYP2C9*3 
alleles are tested for, then the 15–20% of African Americans with an alternative CYP2C9 
variant will be assumed to have the “normal” genotype. Warfarin dosing based on this 
assumption may result in significant overdosing in this population, placing patients at risk 
for bleeding.28 At the University of Illinois Hospital and Health Sciences System (UI 
Health), approximately half of the patient population is black, so care was taken to choose a 
genotyping platform that captured variability unique to those of African ancestry.
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Informatics considerations
There must be a process in place for ordering genetic tests, which may or may not include a 
process for recommending or suggesting genetic testing for a particular patient or patient 
population at the time of drug prescribing. For example, at UF Health, a CYP2C19 genetic 
test order is included by default on the post-PCI order set so that every patient undergoing 
PCI receives genetic testing, unless the testing was conducted previously or the physician 
deselects the defaulted order.31
Further informatics support is needed to enter genotype results into the EHR. Genotype 
results reported in the format of nucleotide base calls (e.g., VKORC1 AG genotype) or 
“star” allele nomenclature (e.g., CYP2C19*1/*2) have little meaning to most clinicians. 
Therefore, a process must be in place to translate genotype data into clinically interpretable 
and actionable information. This is often done through the laboratory report accompanying 
each test result. In addition, clinical decision support tools may be developed to assist the 
clinician with interpreting results and their implications for drug therapy at the point of 
prescribing. For example, at UF Health, an alert appears within the EHR if the physician 
orders clopidogrel for a patient with a loss-of-function variant, notifying the clinician of the 
potential for reduced clopidogrel effectiveness and providing prescribing information, 
including contraindications, for alternative agents.31 The clinician may order an alternative 
agent by selecting this option within the alert or bypass the alert and continue clopidogrel if 
deemed appropriate. In other instances, a clinical pharmacist provides drug therapy 
recommendations to the primary medical team.30,32
Education and consultative support
Before the implementation of pharmacogenetic testing, education is required to inform the 
clinical staff of the availability of testing, data supporting pharmacogenetic testing, the 
process for ordering and interpreting test results, and who to contact if questions arise. 
Clinician education may be oral or written and can occur in formal grand rounds 
presentations, less formal group or one-on-one conferences, or written clinical practice 
support tools (e.g., quick-reference charts to support genotype ordering or interpretation). 
Inservice programs may also be necessary to educate nursing, administrative, and laboratory 
staff and others involved in the patient’s care. Once testing is launched, additional ongoing 
education is required to provide information to new clinicians and reinforce information for 
others. A process should also be in place to assist clinicians with questions regarding 
genotype results or unique patient cases. The development of patient and community 
education support and materials is an important component of the implementation process. 
Pharmacists can play key roles in this regard, whether as part of multidisciplinary teams 
caring for the patient, as clinicians providing consultations for medication-related questions, 
or as members of a formal pharmacogenetic consultation service.
Quality metrics and outcomes assessment
Most pharmacogenetic clinical implementations also incorporate ongoing assessment of 
quality and safety metrics to evaluate continuous quality-improvement measures, patient and 
medication safety, and clinical, economic, or other outcomes. Important quality assessment 
metrics that are commonly reported include genetic test ordering rate, test turnaround time, 
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and action taken in response to the results.30–32,41,42 Patient and medication safety 
assessment metrics may be specific to the gene–drug pair being implemented (e.g., rate of 
alternative therapy use when indicated by genotype). In the case of genotype-guided 
warfarin dosing or antiplatelet selection, safety metrics might include clinical predictors 
(e.g., age, prior bleeding event, concomitant medications) or laboratory measures of 
bleeding risk. Additional documentation of outcomes with a pharmacogenetics program may 
be important to support continuation of the program, particularly if the hospital pays for the 
testing. In the case of genotype-guided warfarin dosing, such outcomes might include the 
time to achieve a therapeutic INR level, the number of INR levels extremely above or below 
goal, and the duration of low-molecular-weight heparin use.29 Important outcomes with 
genotype-guided antiplatelet selection might include the occurrence of major adverse 
cardiovascular or bleeding events, especially in the early period after PCI when hospitals 
may be penalized for excess readmissions per the Centers for Medicare and Medicaid 
Services Hospital Readmissions Reduction Program.43
Practice models of inpatient pharmacogenetics implementation
The following section describes pharmacogenetics implementation programs at three 
institutions and highlights the operational elements and contributions of pharmacists to each 
program. Additional information, including genotyping procedures, is provided in Table 1.
UF Health
The UF Health Personalized Medicine Program (PMP) was launched in 2012 as a 
pharmacist-led multidisciplinary team effort, with members including experts in 
pharmacogenetics, molecular pathology, clinical care, health informatics, and healthcare 
administration. The goal of the UF Health PMP is to develop, implement, study, and refine 
methods that allow genetic information to be used as a routine part of patient care. 
CYP2C19 testing to predict patient response to clopidogrel after PCI was selected as the 
initial pharmacogenetics implementation based on the evidence described above.
A number of steps were taken to prepare for the implementation of the CYP2C19 testing 
program, including establishing the genotype testing procedures, building clinical decision 
support (i.e., best-practice advisory) to provide test interpretation and clinical 
recommendations based on genetic information, and providing education to physicians and 
other healthcare professionals at UF Health.31,33 A multidisciplinary PMP subcommittee to 
the P&T committee was established to assist with many of these steps and provide oversight 
of the PMP initiative. The subcommittee includes clinical pharmacists with expertise in 
medication safety, pharmacogenetics, drug information, or informatics. The committee 
defined the population to be targeted for testing and the specific genotypes and metabolic 
phenotypes that would be the basis for pharmacogenetic recommendations. The committee 
also assisted with wording of pathology reports to accompany genotype results and the best-
practice advisory. The PMP subcommittee continues to serve an important role by evaluating 
new evidence as it arises to determine whether any change in procedures is warranted. For 
example, while triple-dose clopidogrel (225 mg) was initially recommended as an option for 
alternative therapy in IMs, the subcommittee voted to remove this option due to the 
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emergence of data showing that this approach may be insufficient for overcoming the effects 
of this loss-of-function genotype.44
When the program began in June 2012, the genotype test order was placed on the 
precatheterization order set, and genotyping was conducted preemptively for patients 
undergoing left heart catheterization with the expectation that many patients would proceed 
to PCI. When the program started billing for CYP2C19 testing, the genotype test order was 
moved to the post-PCI order set, where it remains today. Because genotyping is included in 
the standard patient care procedures for this patient population, additional patient consent for 
genetic testing is not needed.
Patients with any combination of two loss-of-function alleles are assigned the PM 
phenotype, while those with a single loss-of-function allele (e.g., CYP2C19*1/*2 or 
CYP2C19*2/*17) are assigned the IM phenotype. Genotype and phenotype results are 
reported in the EHR under the laboratory reports tab and are accompanied by an 
interpretative laboratory report. A clinical pharmacist reviews CYP2C19 test results and 
recommends alternative antiplatelet therapy with prasugrel or ticagrelor for PMs or IMs who 
underwent PCI in the absence of contraindications. Patient education materials about 
CYP2C19 genotyping are provided to physicians and nurses in the clinical setting, are 
available to clinicians via a direct link in the EHR alert, and are accessible to clinicians and 
patients through the program’s website (http://personalizedmedicine.ufhealth.org). Patients 
can also access their genotype results through the patient portal of the EHR.
Initial program metrics were published in 2013 and showed that the majority of patients 
undergoing PCI received a genetic test, with an increased rate of test adoption over the initial 
year of the program.31 Approximately 30% of the patients tested had the IM or PM 
phenotype, and 70% of these patients were switched to an alternative agent after PCI. The 
effect of genotype-guided antiplatelet drug selection on clinical outcomes has been reported 
elsewhere, revealing that patients with the IM or PM phenotype who remained on 
clopidogrel had significantly worse cardiovascular outcomes than those who were switched 
to alternative antiplatelet therapy (i.e., prasugrel or ticagrelor).43
University of North Carolina
An algorithm that uses CYP2C19 genotype and clinical factors to guide antiplatelet therapy 
in high-risk patients undergoing PCI was implemented at the University of North Carolina 
(UNC) in April 2012 as the standard of care.32 The development, approval, and 
implementation of this algorithm were driven by the physician director of the cardiac 
catheterization laboratory and completed in collaboration with the interventional cardiology 
attending physicians and clinical pharmacy specialists supporting the inpatient cardiology 
service. Clinical pharmacy also played a key leadership role in the education of physicians 
and other healthcare professionals on the available evidence to facilitate implementation of 
this practice model.
The 2011 American College of Cardiology Foundation (ACCF)/American Heart Association 
(AHA)/Society for Cardiovascular Angiography and Interventions PCI guidelines state that 
a genotype-guided approach “might be considered” in high-risk patients, such as those with 
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an unprotected left main coronary artery or a bifurcating left main coronary artery or those 
undergoing PCI on the last patent coronary artery (class IIb, level of evidence: C).45 In 
accordance with these guidelines, CYP2C19 genotype testing is recommended in patients 
undergoing PCI at UNC for either acute coronary syndrome or stable coronary artery disease 
with high-risk anatomical findings. Consequently, the genotype test is not a defaulted order 
in the post-PCI order set and needs to be actively ordered after angiography-guided risk 
stratification by the interventional cardiologist (i.e., reactive strategy). Similar to UF Health, 
patient consent for genotyping occurs as part of the clinical consent process for the PCI and 
its associated care. Genotype results are uploaded into the molecular genetics laboratory 
section of the EHR and accompanied by an interpretation. The report also includes a brief 
description of clopidogrel clinical pharmacology and the relevance of the detected alleles.
After risk stratification, the physician initiates treatment with a loading dose of either 
prasugrel or clopidogrel based on patient-specific clinical factors (e.g., indication for PCI, 
risk factors for bleeding, prior use of a P2Y12 inhibitor) and orders the CYP2C19 genotype 
test if indicated. At UNC, approximately 30% of patients are initiated on prasugrel therapy 
before the genotype test results are available. Presentation with an acute myocardial 
infarction and prasugrel use on admission are the most common indications for this 
approach.32 Consistent with CPIC guidelines,8 prasugrel or ticagrelor is recommended if the 
patient is a CYP2C19 IM or PM, while standard-dose clopidogrel (75 mg/day) is the 
recommended maintenance therapy in CYP2C19 EMs, RMs, and UMs. Prasugrel is the 
most commonly prescribed alternative therapy, and triple-dose clopidogrel (225 mg/day) is 
not recommended.
After receiving the genotype test report, a clinical pharmacist follows up with the physician 
to recommend either continuation of or a change to the P2Y12 inhibitor. Changes in therapy 
are communicated to the nursing staff and patient and occur either before discharge or after 
discharge via telephone follow-up. Based on the initial experience at UNC, approximately 
half of the genotype-driven changes in therapy occur before hospital discharge; the 
remaining half occur after discharge in the outpatient setting.
The UNC practice model has several unique features. First, genotype testing targets high-
risk patients undergoing PCI following risk stratification by the interventional cardiologist. 
Second, this effort was not driven by a large, institutionalized PMP that spans multiple 
practice settings. In contrast, the development and implementation of this genotype-guided 
treatment algorithm were championed and driven by physician leadership in cardiology 
(most notably, the director of the cardiac catheterization laboratories) in collaboration with 
clinical pharmacy specialists. Third, the UNC practice model does not currently employ 
clinical decision support tools within the EHR. Thus, interdisciplinary collaboration and 
communication among physicians, clinical pharmacists, and nurses and rigorous follow-up 
with the patients and their providers have proven critical to effectively obtain, interpret, and 
use CYP2C19 genotyping to guide P2Y12 inhibitor selection in practice. Consequently, 
genotype test results can now be obtained and interpreted as routine laboratory test results 
and utilized to optimize therapeutic decision-making. This is particularly important because 
automated prompts within the EHR are not currently available to alert clinicians about the 
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genotype result. The sustainability of this practice model over time, as well as its impact on 
clinical outcomes, is being actively investigated.
University of Illinois
UI Health PMP is a clinical and research initiative with the primary goal of improving 
pharmacotherapy in patients by increasing personalization of drug selection and dosing. 
Central to the program is its consultation service, which uses both clinical and genetic 
information to provide dosing recommendations for the initiation of warfarin therapy as well 
as antiplatelet therapeutic selection in patients undergoing PCI. The service team is led by 
pharmacists but also includes members from UI Health molecular pathology laboratory, 
health informatics, department of medicine, and health system administration.
Pharmacogenetic testing at UI Health is currently optional, with the decision on whether to 
perform genetic testing left to the medication prescriber. However, when the warfarin 
pharmacogenetics program began in 2012, testing was automatically conducted for all 
patients newly starting warfarin.30 This changed in early 2014, after the publication of 
clinical trial data led clinicians to question the added benefit of genotyping over warfarin 
dosing based on clinical information alone.25 At that time, testing for warfarin dosing 
became optional. Since the switch from automatic to optional genotyping, genotype testing 
has been ordered for approximately 50% of patients starting warfarin.
When a genetic test is ordered, a consultation by the PMP is automatically generated. 
Simultaneously, a technician in the molecular pathology laboratory receives an electronic 
alert about the genetic test order. Once the blood sample arrives at the laboratory, the 
laboratory technician contacts the PMP pharmacist to confirm that genotyping is appropriate 
(e.g., the patient has no recent history of warfarin use) before proceeding with testing. 
Genotyping is performed at 10 a.m. each day of the week. Blood samples arriving at the 
laboratory before 10 a.m. are genotyped that day, with the results available by 4 p.m. Blood 
samples arriving in the laboratory after 10 a.m. are processed the following day. Warfarin is 
administered at 9 p.m. each day; thus, this model allows for genotype-informed dosing by 
the second dose for more than 90% of patients. The PMP pharmacist recommends a 
clinically informed dose (determined using the www.warfarindosing.org algorithm and 
clinical judgment) for the first dose (i.e., dose before the return of genotyping results) when 
possible. Otherwise, determination of the first dose is left to the discretion of the provider.
Once available, genotypes are entered into the laboratory results section of the EHR. The 
PMP pharmacist combines genotype data with clinical information retrieved from the EHR 
and determines an estimated effective dose using a combination of dosing algorithms 
available at www.warfarindosing.org and clinical judgment. Dose recommendations are 
communicated to the prescriber via a note in the patient’s medical record and direct 
discussion. The patient is followed by the PMP pharmacist (with daily notes written) until 
the patient either achieves two consecutive therapeutic INRs or is discharged from the 
hospital. At the time of hospital discharge, the PMP pharmacist recommends that the patient 
be referred to the pharmacist-managed, outpatient UI Health antithrombosis clinic for 
follow-up.
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Prescriber acceptance of warfarin dosing recommendations has steadily increased since 
pharmacogenetics implementation. Currently, approximately 95% of warfarin dose 
adjustments in patients followed by the service are within 0.5 mg of PMP pharmacist 
recommendations. In addition, preliminary results based on data collected from the first 16 
months of implementation suggest that, compared with historical controls, patients receiving 
genotype-guided warfarin doses by the pharmacist-led UI Health PMP reach their targeted 
INR values at a faster rate and are more likely to have a therapeutic INR at discharge, fewer 
extreme INR values, and a shorter duration of low-molecular-weight heparin use during 
warfarin initiation.29
Clopidogrel pharmacogenetic testing was implemented at UI Health in 2014 and, as with 
warfarin, is ordered at the discretion of the prescriber. The UI Health PMP strongly 
recommends CYP2C19 testing for high-risk patients, as defined by the ACCF/AHA PCI 
guidelines discussed above, with testing targeted to those prescribed clopidogrel. Once an 
order is placed and the blood sample arrives in the molecular pathology laboratory, a 
laboratory technician contacts the PMP pharmacist to confirm that genotyping is 
appropriate. Clopidogrel genotyping and warfarin genotyping are conducted simultaneously, 
so genotyping results are usually available either the same day or the next day, allowing an 
antiplatelet recommendation to be made before most patients are discharged from the 
hospital. Once the results are available, they are placed in the same EHR laboratory results 
section as warfarin genotyping results. The PMP pharmacist then recommends to continue 
clopidogrel (for EMs, RMs, and UMs) or to consider another antiplatelet medication (for 
IMs or PMs) if no contraindications exist. This recommendation is communicated to the 
prescriber via a consultation note in the EHR as well as via direct discussion.
Discussion
All three programs currently use reactive versus preemptive genotyping, meaning that 
genotyping is done at the time of prescribing. While this is the only feasible approach under 
the current third-party payment structure, which only reimburses for reactive testing, it 
creates a challenge because test results are not readily available at the time of prescribing. 
All three sites also follow CPIC guidelines for drug therapy recommendations based on 
genetic test results. However, while CPIC guidelines for clopidogrel focus on patients who 
undergo PCI for an acute coronary event, the UF Health program targets all patients 
undergoing PCI; the UNC and UI Health programs target high-risk patients undergoing PCI, 
whether the procedure is done electively or for an acute coronary event. Genotype test 
turnaround time varies among programs, as shown in Table 1, with a longer turnaround time 
at UF Health where samples must be transported to an offsite laboratory. The latter may 
serve as a model for other institutions where genotyping facilities are not immediately 
available. There are some differences among programs in the use of clinical decision support 
tools, and while clinical pharmacists serve vital roles in each program, the nature of roles 
varies somewhat among programs. The UF Health and UI Health programs are championed 
by pharmacists who led the initial implementation efforts and continue to serve as program 
leaders. While the UNC model is a physician-led model, pharmacists serve as leaders of the 
educational efforts and have critical roles in facilitating test interpretation and prescribing 
decisions. While only three programs are highlighted in this article, there are examples of 
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additional programs implementing pharmacogenetics in the inpatient setting across the 
country.46–48
Conclusion
Pharmacogenetics has emerged into clinical practice in the inpatient setting, with 
pharmacists assuming important roles in facilitating the application of genetic information to 
drug therapy decisions. Pharmacists are serving as important members of multidisciplinary 
teams in leading pharmacogenetics programs in hospitals, including CYP2C19 testing to 
predict clopidogrel response and CYP2C9 and VKORC1 testing to predict warfarin dose 
requirements. Each implementation involves critical steps with which pharmacists may 
either lead or assist, including reviewing the evidence supporting implementation, obtaining 
necessary institutional approval, educating prescribers, building user-friendly clinical 
decision support tools to assist with interpreting genotype test results, and applying results to 
actionable prescribing decisions. Once implementation is in place, pharmacists can serve 
vital roles in providing genotype-guided therapy, assessing metrics to ensure patient safety 
and efficient delivery of therapy based on genotype, and examining important outcomes to 
evaluate the value of pharmacogenetics implementation. Therefore, it is important for 
pharmacists practicing in inpatient settings to be prepared to manage drug therapy in the age 
of pharmacogenetics. Moreover, given that genotype test results may not be available until 
after the patient is discharged from the hospital, pharmacists practicing in ambulatory care 
settings should also be prepared to adjust drug therapy according to genotype results.
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Appendix—Genotyping tests available for polymorphisms relevant to 
clopidogrel and warfarin dosing, as of March 2016
Clopidogrel/CYP2C19
• Spartan RX CYP2C19 Test System (Spartan Bioscience, Ottawa Ontario, 
Canada)
• TAG CYP2C19 Kit V3 (Luminex Corp., Madison, WI)
• INFINITI CYP2C19 Assay (AutoGenomics, Vista, CA)
• Roche AmpliChip CYP450 microarray (Roche Molecular Systems, Pleasanton, 
CA)
Warfarin/CYP2C9 and VKORC1
• eSensor Warfarin Sensitivity Test (GenMark Diagnostics, Carlsbad, CA)
• eQ-PCR LC Warfarin Genotyping kit (TrimGen, Sparks Glencoe, MD)
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• Gentris Rapid Genotyping Assay CYP2C9 & VKORC1 (ParagonDx, 
Morrisville, NC)
• INFINITI 2C9 & VKORC1 Multiplex Assay for Warfarin (AutoGenomics)
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KEY POINTS
• Evidence supports the incorporation of genotype information into prescribing 
decisions for a number of drugs commonly initiated in the inpatient setting.
• Pharmacists are serving as important members of multidisciplinary teams in 
leading pharmacogenetics programs in hospitals, including CYP2C19 testing 
to predict clopidogrel response and CYP2C9 and VKORC1 testing to predict 
warfarin dose requirements.
• Pharmacists must be prepared to optimize drug therapy for hospitalized 
patients in this age of pharmacogenetics.
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Figure 1. 
Operational elements of an inpatient models of pharmacogenetics programs and questions to 
consider. CPIC = Clinical Pharmacogenetics Implementation Consortium.
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Table 1
Comparison of Pharmacogenetic Practice Models at Three Institutionsa
Variable
University of Florida 
(UF) University of Illinois (UI) at Chicago
University of North 
Carolina (UNC), 
Chapel Hill
Gene(s)/drug pair(s) CYP2C19/clopidogrel CYP2C9, VKORC1/warfarin; CYP2C19/clopidogrel C-YP2C19/clopidogrel
Regulatory bodies 
requiring approval
P&T committee and 
clinical decision support 
committee
P&T committee and anticoagulation task force for 
warfarin genetic testing; none for CYP2C19 testingb
Noneb
Genotyping location UF Health pathology 
laboratory located 
approximately 3 miles 
from the medical center
UI Health molecular pathology laboratory located within 
the medical center
UNC McLendon 
molecular genetics 
laboratory located 
within the medical 
center
Genotype platform and 
alleles detected
eSensor XT-8 (GenMark 
Diagnostics, Carlsbad, 
CA)
CYP2C19*2, 
CYP2C19*3, 
CYP2C19*4, 
CYP2C19*5, 
CYP2C19*6, 
CYP2C19*8, 
CYP2C19*17
eSensor XT-8 (GenMark Diagnostics)
VKORC1 c.-1639G>A; CYP4F2 1347G>A (V433M); 
CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, 
CYP2C9*11, CYP2C9*14, CYP2C9*15, CYP2C9*16; 
CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, 
CYP2C19*6, CYP2C19*8, CYP2C19*17
TaqMan (Life 
Technologies, Foster 
City, CA)
CYP2C19*2, 
CYP2C19*3, 
CYP2C19*17
Average genotype 
turnaround time
2–4 business days 24 hr 1 business day
Clinical decision support Available in the form of a 
best-practice advisory in 
the EHR (Epic, Verona, 
WI) to alert prescriber 
when clopidogrel is 
ordered for a patient with 
a loss-of-function 
genotype
Alert in the EHR (Cerner Powerchart, Brooklyn, NY) 
about option of genetic testing that appears at the time 
warfarin is ordered for adult age ≥18 yr with no record of 
warfarin use within 6 mo; prescriber must respond “yes” 
or “no” to the option of genotyping to proceed with the 
order; no clinical decision support for clopidogrel
Not available
a
P&T = pharmacy and therapeutics, EHR = electronic health record, PCI = percutaneous coronary intervention.
b
Developed in accordance with the American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular 
Angiography and Interventions PCI guidelines and approved by the cardiac catheterization laboratory attending physicians in collaboration with 
clinical pharmacy specialists supporting the inpatient cardiology service.
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